

NEWS RELEASE

Cell Therapies and Teijin Announce Strategic Collaboration to Expand Access to Advanced Cell and Gene Therapies in Japan and the Asia Pacific Region

October 1, 2025 — [Cell Therapies Pty Ltd.](#) (“Cell Therapies”) and [Teijin Limited](#) announced today that they have signed a Memorandum of Understanding (MoU) to strengthen regional infrastructure for cell and gene therapies (CGT), leveraging advanced GMP capabilities and cross-border collaboration to accelerate development and improve patient access across Japan and the wider Asia Pacific region.

This partnership will combine Cell Therapies’ long-standing expertise as Australia’s leading CGT CDMO with Teijin’s strong manufacturing capabilities in CGT and regenerative medicine via their group companies [Teijin Regenet Co., Ltd](#) and [Japan Tissue Engineering Co., Ltd.](#) (J-TEC) in Japan. The collaboration aims to streamline access to regional markets by enabling cross-border clinical trial and commercial supply, knowledge exchange, and regulatory alignment to support innovative CGT programs.

Through this collaboration, the companies intend to:

- Expand regional GMP manufacturing capacity for cell and gene therapies (CGT)
- Enable efficient technology transfer and multi-site delivery across APAC
- Facilitate clinical trial and market access for advanced therapies in Japan and Australia
- Build long-term infrastructure and capability through joint training and workforce development initiatives



Teijin Regenet Iwakuni Factory



Cell culture facility of Cell Therapies

CELL THERAPIES: Bev Menner, Cell Therapies CEO

“This collaboration with Teijin represents an exciting step toward building a truly connected CGT manufacturing network across the Asia Pacific region,” said Bev Menner, CEO of Cell Therapies. “Japan is a critical hub for innovation and patient access, and by combining Teijin’s expertise with our capabilities, we can deliver streamlined, reliable pathways for clinical trials and commercial supply. Our shared goal is to expand access and accelerate delivery of life-changing therapies to patients across the region.”

Teijin: Takayuki Nakano, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited

“We are delighted to partner with Cell Therapies to enhance access to next-generation therapies for patients in Japan and beyond,” said Takayuki Nakano of Teijin Limited. “This MoU underscores our commitment to strengthening advanced manufacturing capabilities, fostering regulatory harmonization, and building a robust supply chain for cell and gene therapies. By working together, we can drive innovation and contribute to improved patient outcomes throughout the region.”

About Cell Therapies Pty Ltd.

[Cell Therapies Pty Ltd](#) (“Cell Therapies”) is Australia’s leading contract development and manufacturing organization (CDMO) dedicated to cell and gene therapies. With over two decades of experience, Cell Therapies supports the development, clinical translation, and commercial manufacture of innovative cell and gene therapies (CGT) including CAR T-cell, mesenchymal stromal cells, and iPSC-derived therapies.

Cell Therapies’ facility, co-located within the Peter MacCallum Cancer Centre in Melbourne, Victoria, holds licenses for clinical and commercial supply of CGTs from the Australian regulator, Therapeutic Goods Administration (TGA), and approval to supply to Japan’s market from the Japanese Ministry of Health Labor and Welfare (MHLW). Cell Therapies operates 13 purpose-built GMP cleanrooms; 10 supporting clinical trial manufacture and 3 large-scale high-throughput suites designed for commercial manufacture with a capacity of up to 2,000 patient doses annually.

Press Contacts

Business and Marketing Team, Cell Therapies Pty Ltd.

enquiries@celltherapies.com

About Teijin’s CDMO Business

[Teijin](#) (TSE: 3401) is a technology-driven global group with two core businesses: high performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 150 companies employing 20,000 people.

Teijin cemented themselves in the regenerative medicine business in 2021, after welcoming industry pioneer J-TEC into their group.

[Teijin CDMO](#), a joint operation between J-TEC and Teijin Regenet, has two modes of expansion: the manufacturing and Sales of regenerative medicine products, and the provision of world class CDMO services. Powered by its CDO base in Chiba Prefecture and its CMO base in Yamaguchi Prefecture, Teijin Regenet is strengthened by its partnerships with domestic and international companies, as well as key academic institutions and National Center.

Press Contacts

Corporate Communication Department, Teijin Limited

pr@teijin.co.jp